Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Intervalo de año de publicación
1.
West Indian med. j ; West Indian med. j;69(3): 154-156, 2021.
Artículo en Inglés | LILACS | ID: biblio-1341891

RESUMEN

ABSTRACT Aripiprazole is an atypical antipsychotic agent which has a partial agonistic effect on dopamine D2 and D3 receptors. It is effective in the treatment of schizophrenia and bipolar disorder. Owing to its partial agonistic effect, hyperactivity of dopamine may occur in the mesolimbic pathway. In the literature, there are few case reports about pathological gambling due to aripiprazole. In this article, there are two case reports of patients who showed pathological gambling behaviour and alcohol abuse and who were under treatment with aripiprazole. The patient had a history of gambling in the past. With the use of aripiprazole, pathological gambling behaviour occurred quickly and with discontinuation of aripiprazole it ended completely. Aripiprazole causes pathological gambling by forming a hyperdopaminergic condition in the mesolimbic dopaminergic pathway. Aripiprazole should be recommended cautiously and carefully to patients who are impulsive and have a history of alcohol/substance abuse.


Asunto(s)
Humanos , Masculino , Adulto , Persona de Mediana Edad , Antipsicóticos/efectos adversos , Agonistas de Dopamina/efectos adversos , Aripiprazol/efectos adversos , Juego de Azar/inducido químicamente
2.
Arq Neuropsiquiatr ; 73(2): 115-8, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25742580

RESUMEN

UNLABELLED: Impulse control disorders (ICD) in Parkinson's disease (PD) have attracted increasing interest. They are characterized by the inability to control the impulse to perform an act that can be detrimental to them or to others. Although dopamine agonists (DA), as a group, have been associated with impulse control disorders (ICD), piribedil has rarely been reported to cause them. METHOD: Case reports of six parkinsonian patients on piribedil presenting pathological gambling (PG). RESULTS: All of the patients presented ICD associated with piribedil use. Two of them received this medication as first treatment and four of them who had developed ICDs secondary to other DA that reappeared with piribedil. CONCLUSION: Despite piribedil is commercially available in only a few countries, it should be considered in the differential diagnosis of PG in patients with PD.


Asunto(s)
Antiparkinsonianos/efectos adversos , Agonistas de Dopamina/efectos adversos , Juego de Azar/inducido químicamente , Enfermedad de Parkinson/tratamiento farmacológico , Piribedil/efectos adversos , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/psicología , Factores de Riesgo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA